Effect of Pantoprazole in the Treatment of Peptic Ulcer Complicated with PUCH (Upper Gastrointestinal Hemorrhage)

医药导报 Pub Date : 2001-01-01 DOI:10.47939/mh.v2i1.104

Tang-lei Shao

引用次数: 3

Abstract

Objective:To evaluate the effect of pantoprazole in the treatment of peptic ulcer. Method:93 patients with active peptic ulcer confirmed by endoscopy were randomly allocated to study group(group A, n=50) and control group (group B, n=43). Pantoprazole was given a dose of 40 mg po at 8 am in group A, and group B received ranitidine 300 mg p.o. at bedtime for 4 weeks. Results:①The mean time of upper abdominal pain regression for group A (4.4 days) was markedly less than that for group B(7.6 days) and the healing rate of ulcer for group A(96.0%) was significantly higher than that for group B(69.8%) with statistical differences (P0.05,P0.01).②In group A and group B, the healing rates of duodenal ulcer were 96.9% and 71.4% respectively, and gastric ulcer were 94.4% and 66.7% respectively. There were significant differences (P0.01,P0.05). Conclusion:Our data show that the effect of pantoprazole in the treatment of peptic ulcer is satisfactory, and gains an advantage over that of ranitidine.

查看原文本刊更多论文

泮托拉唑治疗消化性溃疡合并上消化道出血的疗效观察

目的:评价泮托拉唑治疗消化性溃疡的疗效。方法:93例经内镜检查证实为活动性消化性溃疡患者，随机分为研究组(A组，n=50)和对照组(B组，n=43)。a组患者给予泮托拉唑40 mg /次，每日8时服用;B组患者给予雷尼替丁300 mg /次，每日睡前服用，连续4周。结果:①A组患者上腹痛平均消退时间(4.4 d)明显少于B组(7.6 d)，溃疡愈合率(96.0%)显著高于B组(69.8%)，差异有统计学意义(差异有统计学意义(0.05,0.01)。②A、B组十二指肠溃疡治愈率分别为96.9%、71.4%，胃溃疡治愈率分别为94.4%、66.7%。两组间差异有统计学意义(分别为0.01、0.05)。结论:泮托拉唑治疗消化性溃疡疗效满意，且优于雷尼替丁。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

医药导报

自引率

0.00%

发文量

18566

期刊介绍： Herald of Medicine Magazine is a professional journal of medicine for domestic and foreign public circulation approved by the Press and Publication Bureau of the Propaganda Department of the Central Committee of the Communist Party of China (CPC), founded in 1982 and published monthly on the 1st of each month under the supervision of the Hubei Provincial Drug Administration and sponsored by Tongji Hospital attached to the Tongji Medical College of Huazhong University of Science and Technology and the Chinese Society of Pharmacology. Herald of Medicine is a source journal of China Science and Technology Paper Statistics of the Ministry of Science and Technology of China (i.e., China Science and Technology Core Journal), and a selected journal of Chinese Core Journals in the General List of Chinese Core Journals of Peking University Library (i.e., Chinese Core Journals). It is included in Chinese databases such as Wanfang Data Source Systematic Journal Group, China Academic Journal Comprehensive Evaluation Database, Chinese Science and Technology Journal Database, China Biomedical Journal Citation Database, and Superstar Domain Publishing. It is included in WHO Western Pacific Region Medical Index (WPRIM), Japan Science and Technology Agency Database (JST), American Chemical Abstracts (CA), International Pharmaceutical Abstracts (IPA), and Ulrich Periodicals Directory (UPD). 2020-2022, it will be listed in the World Journal Clout Index (WJCI) Report (Science and Technology) for consecutive years. Recognized by the state as a promotional media for publishing prescription drug advertisements.